CagriSema is an experimental weekly injection combining GLP-1 receptor agonist semaglutide with cagrilintide, a drug targeting the amylin pathway to mimic pancreatic hormones that regulate hunger and fullness

From the articleNovo's CagriSema helped women lose 25% of weight on average, analysis shows | ReutersAlso in Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis